OncoPharm

John Bossaer
undefined
Feb 6, 2020 • 17min

NK - 1 Antagonist Drug Interactions

Drug-drug interactions are a key consideration when determining which NK-1 antagonist to use in patients receiving highly emetogenic chemotherapy. We discuss the issues for (fos)aprepitant, netupitant, & rolapitant. A nice aprepitant review (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595939/) and the case for an aprepitant-vincristine interaction (https://doi.org/10.1177/1078155219870840).
undefined
Jan 30, 2020 • 14min

Tazemetostat

All the need-to-know items about the latest #oncopharm approved drug, tazemetostat, to start the Pod. We end (9:15) with a brief discussion of how gut bacteria may lead to gemcitabine resistance.
undefined
7 snips
Jan 23, 2020 • 17min

Bendamustine

Dive into the world of bendamustine, a chemotherapeutic agent known for its unique dual mechanism of action. Discover its impressive efficacy against lymphomas and compare its results with traditional therapies. The discussion also highlights the intricacies of bendamustine's administration and metabolism, emphasizing the impact of CYP1A2 and how smoking can affect treatment outcomes. Plus, learn about the nuances of its different formulations and what makes this drug stand out in cancer treatment.
undefined
Jan 16, 2020 • 16min

Avapritinib

New Drug Update! We discuss the efficacy and safety data surrounding avapritinib's approval as well as its likely role in GIST management.
undefined
Jan 9, 2020 • 16min

Safety Signals & 6 - MP Hepatotoxicity

How common are upon safety concerns from FDA on newly approved #oncopharm agents? Does the accelerated approval process lead to more safety updates? We discuss (https://doi.org/10.1634/theoncologist.2019-0653). We also look at a possible way to mitigate 6-MP hepatoxicity (5:45) using allopurinol (https://doi.org/10.1080/10428194.2019.1702183). Finally (10:55) we review the most recent FDA indications for olaparib and pembrolizumab.
undefined
Jan 2, 2020 • 13min

Trastuzumab Deruxtecan

Kicking off the 2020 Pod season with the last FDA-approval of 2019 - trastuzumab deruxtecan.
undefined
Dec 26, 2019 • 16min

Enfortumab-vedotin (& Asciminib)

Closing out the year discussing FDA's approval of enfortumab-vedotin for urothelial cancer and a new, but pharmacologically unique, TKI with activity in CML (12:45). Happy New Year!
undefined
Dec 19, 2019 • 15min

Arsenic Sauce

The Foundations of #OncoPharm series combines with a thematic critique of an animated Holiday classic to examine the links between The Grinch and Arsenic Trioxide.
undefined
Dec 12, 2019 • 21min

ASH '19 Updates

Reviewing pertinent abstracts from ASH's 2019 annual meeting. Abstracts discussed: LBA-1 (blinatumomab), 2640 (venetoclax-azoles interactions), 2639 (FLAG/CLAG vs. CPX-351 in sAML), LBA-6/862/860 (myeloma), and 3310 (PK-targeted dosing of melphalan for autoHSCT). Search here: https://ash.confex.com/ash/2019/webprogram/start.html
undefined
Dec 5, 2019 • 17min

Dose Dense AC

The Landmarks in #OncoPharm series returns with dose-dense AC, published in JCO in 2003 by Citron et al. Link: https://www.ncbi.nlm.nih.gov/pubmed/12668651

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app